Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.66 |
| ▸ | MAP2K2 | P36507 | 5/20 | 0.66 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.66 |
| ▸ | RAF1 | P04049 | 1/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.66 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.66 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.66 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.66 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.66 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.66 |
| ▸ | SMC2 | O95347 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.64 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.64 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.64 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4546050 | 0.92 | MAP2K1 (0.65) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL5743948 | 0.91 | MEN1 (0.70) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL4546005 | 0.90 | MAP2K1 (0.78) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL17636313 | 0.90 | MAP2K1 (0.64) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL5742991 | 0.90 | MAP2K1 (0.62) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL18752905 | 0.89 | MAP2K1 (0.62) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL5742105 | 0.88 | MAP2K1 (0.62) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL5743728 | 0.88 | MAP2K1 (0.59) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL4546045 | 0.86 | MAP2K1 (0.58) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB | |
| SCHEMBL6070249 | 0.85 | MAP2K1 (0.58) | MAP2K1MAP2K2CSNK2A2RAF1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106225-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. | 2006-05-18 | — | — | US | claimed |
| EP-1482944-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-19 | — | — | EP | claimed |
| EP-1482944-A2 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20030216460-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003077855-A2 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | claimed |
| US-20060106225-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. | 2006-05-18 | — | — | US | disclosed |
| EP-1482944-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1482944-A2 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20030216460-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003077855-A2 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106225-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CCNT1 | MAP2K1 130/4885MAP2K2 115/4885CSNK2A2 1084/4885 |
| US-20030216460-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CCNT1 | MAP2K1 110/4885MAP2K2 115/4885CSNK2A2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.